DBV Technologies (NASDAQ:DBVT) Reaches New 12-Month High – Time to Buy?

DBV Technologies S.A. (NASDAQ:DBVT) shares hit a new 52-week high during trading on Wednesday . The company traded as high as $19.51 and last traded at $19.3660, with a volume of 146034 shares traded. The stock had previously closed at $17.16.

Wall Street Analysts Forecast Growth

DBVT has been the subject of a number of analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of DBV Technologies in a research report on Monday. HC Wainwright reissued a “buy” rating and issued a $20.00 target price (up from $16.00) on shares of DBV Technologies in a research note on Wednesday, October 29th. Guggenheim assumed coverage on DBV Technologies in a report on Wednesday, December 3rd. They set a “buy” rating and a $35.00 price target for the company. Wall Street Zen raised DBV Technologies from a “sell” rating to a “hold” rating in a research report on Friday, November 28th. Finally, Zacks Research raised shares of DBV Technologies from a “strong sell” rating to a “hold” rating in a research report on Monday, September 29th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, DBV Technologies presently has an average rating of “Moderate Buy” and a consensus price target of $20.81.

DBV Technologies Stock Performance

The stock has a fifty day simple moving average of $14.35 and a 200 day simple moving average of $11.23. The firm has a market cap of $746.69 million, a P/E ratio of -3.71 and a beta of -1.10.

Hedge Funds Weigh In On DBV Technologies

Several hedge funds and other institutional investors have recently bought and sold shares of DBVT. New York State Common Retirement Fund purchased a new stake in shares of DBV Technologies during the 3rd quarter valued at about $34,000. Two Sigma Investments LP purchased a new position in shares of DBV Technologies during the third quarter valued at approximately $167,000. Citadel Advisors LLC purchased a new position in shares of DBV Technologies during the third quarter valued at approximately $220,000. DLD Asset Management LP bought a new position in DBV Technologies during the third quarter valued at approximately $250,000. Finally, Nan Fung Trinity HK Ltd. purchased a new stake in DBV Technologies in the second quarter worth approximately $340,000. Institutional investors own 71.74% of the company’s stock.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.